- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03481881
Pharmacokinetics of Drugs Administered to Children
December 7, 2023 updated by: Duke University
Pharmacokinetics of Drugs Administered to Children Per Standard of Care
This is a prospective study of children <21 years of age with the goal of characterizing the PK of drugs administered per standard of care as prescribed by the treating caregiver.
Study Overview
Study Type
Observational
Enrollment (Estimated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rachel G Greenberg, MD
- Phone Number: 9196684725
- Email: rachel.greenberg@duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University
-
Contact:
- Rachel Greenberg, MD
- Phone Number: 919-668-4725
- Email: rachel.greenberg@duke.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Children (<21 years of age) receiving drugs per standard of care as prescribed by treating caregiver
Description
Inclusion Criteria:
- Children (< 21 years of age) who are receiving understudied drugs of interest per standard of care as prescribed by their treating caregiver
Exclusion Criteria:
- Failure to obtain consent/assent (as indicated)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the curve (AUC)
Time Frame: Data will be collected throughout the hospital or outpatient stay up to 90 days
|
Data will be collected throughout the hospital or outpatient stay up to 90 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum concentration (Cmax)
Time Frame: Data will be collected throughout the hospital or outpatient stay up to 90 days
|
Data will be collected throughout the hospital or outpatient stay up to 90 days
|
Time to achieve maximum concentration (Tmax)
Time Frame: Data will be collected throughout the hospital or outpatient stay up to 90 days
|
Data will be collected throughout the hospital or outpatient stay up to 90 days
|
Absorption rate constant (ka)
Time Frame: Data will be collected throughout the hospital or outpatient stay up to 90 days
|
Data will be collected throughout the hospital or outpatient stay up to 90 days
|
Elimination rate constant (kel)
Time Frame: Data will be collected throughout the hospital or outpatient stay up to 90 days
|
Data will be collected throughout the hospital or outpatient stay up to 90 days
|
Half-life (t1/2)
Time Frame: Data will be collected throughout the hospital or outpatient stay up to 90 days
|
Data will be collected throughout the hospital or outpatient stay up to 90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 14, 2013
Primary Completion (Estimated)
August 14, 2033
Study Completion (Estimated)
August 14, 2033
Study Registration Dates
First Submitted
March 14, 2018
First Submitted That Met QC Criteria
March 22, 2018
First Posted (Actual)
March 29, 2018
Study Record Updates
Last Update Posted (Actual)
December 8, 2023
Last Update Submitted That Met QC Criteria
December 7, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- Pro00042519
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric ALL
-
Samsung Medical CenterMinistry of Health, Republic of KoreaRecruitingRelapsed Pediatric AML | Refractory Pediatric AML | Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid TumorKorea, Republic of
-
University of BirminghamCompletedCancer | Pediatric ALL | Pediatric Solid Tumor | Pediatric AMLUnited Kingdom, Australia, Netherlands
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ Transplantation in ChildrenCompletedPediatric Heart Transplantation | Pediatric Heart Transplant Recipients | Pediatric Cardiac TransplantationUnited States
-
University Hospital, Strasbourg, FranceTerminatedPediatric Lung Ultrasound | Pediatric Chest Radiography | Pediatric Lung DiagnosisFrance
-
TC Erciyes UniversityCompletedPediatric Cancer | Pediatric Brain Tumor | Pediatric Solid TumorTurkey
-
National Institute of Allergy and Infectious Diseases...National Heart, Lung, and Blood Institute (NHLBI)TerminatedPediatric Heart Transplantation | Pediatric Heart Transplant RecipientsUnited States, Canada
-
University of CalgaryCanadian Institutes of Health Research (CIHR); Alberta Children's Hospital; Stollery... and other collaboratorsNot yet recruitingPediatric Cancer | Pediatric Hematology
-
Children's Healthcare of AtlantaEmory UniversityCompletedPediatric Preoperative Anxiety, Pediatric CopingUnited States
-
Hospital Moinhos de VentoNot yet recruitingAdolescent | Telemedicine | Critical Care | Pediatric | Intensive Care Units, Pediatric
-
Samsung Medical CenterMinistry of Health, Republic of KoreaNot yet recruitingRelapsed Pediatric Solid Tumor | Refractory Pediatric Solid TumorKorea, Republic of
Clinical Trials on Standard of care drug
-
Berlin Heals GmbHRecruitingSystolic Left Ventricular DysfunctionSwitzerland, Croatia, Germany, Spain, Serbia, Bosnia and Herzegovina, Bulgaria, Greece, North Macedonia, Poland, Czechia
-
Cedars-Sinai Medical CenterCompleted
-
BioMarck Pharmaceuticals, Ltd.CompletedNon Small Cell Lung Cancer Stage IIIBIndia
-
Novartis PharmaceuticalsTerminatedTransplant Associated Microangiopathy TAMFrance, United States, Germany
-
University of ChicagoRecruitingCancer | Advanced Solid Tumor | Advanced Cancer | Behavior Disorders | Mental Health IssueUnited States
-
University Hospital Inselspital, BerneUMC Utrecht; Cliniques universitaires Saint-Luc- Université Catholique de Louvain and other collaboratorsCompleted3 or More Chronic Conditions for 6 Months or Longer | 5 or More Regular DrugsBelgium, Ireland, Netherlands, Switzerland
-
University Hospital Inselspital, BerneUMC Utrecht; Cliniques universitaires Saint-Luc- Université Catholique de Louvain and other collaboratorsCompletedOPtimising thERapy to Prevent Avoidable Hospital Admissions in the Multimorbid Older People (OPERAM)3 or More Chronic Conditions for 6 Months or Longer | 5 or More Regular DrugsBelgium, Ireland, Netherlands, Switzerland
-
University Hospital Southampton NHS Foundation...University College, London; Bill and Melinda Gates FoundationCompletedRespiratory InfectionsUnited Kingdom
-
brett rasmussenCompleted
-
Johns Hopkins UniversityRecruitingCompartment Syndrome of Leg | Extracorporeal Membrane Oxygenation Complication | Limb Ischemia, Critical | Limb IschemiaUnited States